Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection.

ABSTRACT: More than half of the world's population lives in areas at risk for dengue virus infection. A vaccine will be pivotal to controlling spread, however, the only licensed vaccine, Dengvaxia, has been shown to increase the risk of severe disease in a subset of individuals. Vaccine efforts are hampered by a poor understanding of antibody responses, including those generated by vaccines, and whether antibody titers can be used as a marker of protection from infection or disease. Here we present the results of an ancillary study to a phase III vaccine study (n = 611). All participants received three doses of either Dengvaxia or placebo and were followed for 6 years. We performed neutralization tests on annual samples and during confirmed dengue episodes (n = 16,508 total measurements). We use mat

SUBMITTER: Salje H 

PROVIDER: S-EPMC8364868 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature